Workflow
Journey Medical (DERM)
icon
Search documents
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
ZACKS· 2025-08-11 14:10
Core Insights - The Medical sector is showing strong performance as the earnings season concludes, particularly among large biotech companies which have reported positive second-quarter results [1][2][9] Company Performance - Gilead Sciences, Inc. reported better-than-expected second-quarter results and raised its annual guidance [2] - Amgen's second-quarter results exceeded expectations in both earnings and sales, leading to an increased revenue and earnings outlook for 2025 [2] - Regeneron also surpassed earnings and sales estimates, achieving year-over-year revenue growth despite a decline in sales of its leading drug Eylea [2] - Biogen's second-quarter results were strong, with both top and bottom-line figures beating estimates, prompting an increase in its full-year guidance [2] Earnings Expectations - Several biotech companies are expected to report earnings surprises, with a focus on three specific companies: Zevra Therapeutics, Inovio Pharmaceuticals, and Journey Medical Corporation [3][9] - The Earnings ESP methodology indicates that stocks with a positive Earnings ESP and a favorable Zacks Rank have a high chance of delivering earnings surprises [4][5] Company Highlights - **Zevra Therapeutics (ZVRA)**: Focused on therapies for rare diseases, with a strong initial uptake of its FDA-approved treatment for Niemann-Pick disease type C. ZVRA has an Earnings ESP of +58.04% and is scheduled to report on August 12, 2025 [6][7] - **Inovio Pharmaceuticals (INO)**: A clinical-stage company developing DNA medicines, with a lead candidate for treating recurrent respiratory papillomatosis. INO has an Earnings ESP of +10.76% and is also set to report on August 12, 2025 [8][10] - **Journey Medical Corporation (DERM)**: Focuses on dermatological treatments and has seen a strong start for its new oral rosacea treatment. DERM has an Earnings ESP of +14.29% and is scheduled to report on August 12, 2025 [11][12]
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire News Room· 2025-08-05 20:01
SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2025 financial results after the U.S. financial markets close on Tuesday, August 12, 2025. J ...
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ZACKS· 2025-08-04 15:00
The market expects Journey Medical Corporation (DERM) to deliver a year-over-year increase in earnings on flat revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, ...
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Globenewswire· 2025-07-14 12:30
Core Insights - Journey Medical Corporation has expanded payer coverage for its product Emrosi™ to 65% of commercial lives in the U.S., a significant increase from 29% in May 2025, which supports the growing prescription demand for the product [1][2] - The company emphasizes its targeted contracting strategy and strong clinical data as key drivers for the adoption of Emrosi, which is expected to become the standard of care for treating rosacea [2] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions, currently offering eight such products [6] - The company is based in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. [6] Product Information - Emrosi™ is indicated for the treatment of inflammatory lesions of rosacea in adults, specifically targeting papules and pustules [4] - The product is available by prescription at specialty pharmacy chains [2] Market Context - Rosacea affects over 16 million Americans and approximately 415 million people worldwide, with significant impacts on patients' self-esteem and social interactions [3] - The condition is most prevalent among adults aged 30 to 50, highlighting a substantial market opportunity for effective treatments like Emrosi [3]
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
Globenewswire· 2025-06-24 12:30
Core Insights - Journey Medical Corporation will be included in the Russell 2000 and Russell 3000 Indexes effective after the close of U.S. equity markets on June 27, 2025, due to the 2025 annual Russell Index reconstitution [1][2] - The inclusion in these indexes is expected to enhance the company's visibility among investors and institutions [2] - Journey Medical's FDA-approved product, Emrosi™, for treating inflammatory lesions of rosacea, is experiencing a strong market entry, with plans to expand access and grow prescription volume [2] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [6][7] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [6] - Founded by Fortress Biotech, Inc., Journey Medical is based in Scottsdale, Arizona [7] Market Context - The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes, which are widely utilized by investment managers and institutional investors [2]
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Globenewswire· 2025-06-20 12:30
Core Viewpoint - Emrosi™ has demonstrated efficacy in treating moderate-to-severe papulopustular rosacea, independent of body weight differences, supporting its FDA approval in November 2024 [1][6][8] Group 1: Clinical Trial Results - Data from two Phase 3 trials (MVOR-1 and MVOR-2) showed that Emrosi can be prescribed without regard to body weight, reducing potential dosing errors [2][5] - In MVOR-1, 75.5% of subjects with body weight ≤ median achieved IGA treatment success with Emrosi compared to 51.0% with doxycycline and 28.2% with placebo [4] - In MVOR-2, 65.0% of subjects with body weight > median achieved IGA treatment success with Emrosi compared to 33.9% with doxycycline and 22.6% with placebo [4] Group 2: Efficacy and Safety - Emrosi showed superior efficacy on both co-primary endpoints compared to placebo and doxycycline, with no significant differences in adverse events reported [5][6] - The most common adverse reaction was dyspepsia, occurring in ≥1% of subjects treated with Emrosi [9] Group 3: Company Overview - Journey Medical Corporation focuses on marketing FDA-approved prescription products for dermatological conditions and currently markets eight such products [11] - The company is based in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. [11]
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
Globenewswire· 2025-06-09 12:30
Core Viewpoint - Journey Medical Corporation is enhancing the visibility of its FDA-approved product Emrosi™ through a feature on "The Balancing Act," aimed at educating patients and healthcare providers about its benefits in treating rosacea [2][3]. Company Overview - Journey Medical Corporation (Nasdaq: DERM) is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [8]. - The company currently markets eight FDA-approved prescription drugs targeting common skin conditions and is based in Scottsdale, Arizona [8]. Product Information - Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) is the lowest-dose oral minocycline available, approved by the FDA in November 2024 for treating inflammatory lesions of rosacea in adults [2]. - Emrosi offers an effective treatment option with a favorable safety profile and is available by prescription at specialty pharmacy chains [2]. Industry Context - Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans and approximately 415 million people worldwide, primarily seen in adults aged 30 to 50 [4]. - The National Rosacea Society reports that over 90% of rosacea patients feel their condition lowers their self-confidence, with significant impacts on social and professional interactions [4].
Journey Medical (DERM) - 2025 Q1 - Quarterly Report
2025-05-15 10:01
Product Launch and Revenue - EmrosiTM received FDA approval on November 1, 2024, for treating inflammatory lesions of rosacea, with initial supply available in March 2025 and sales promotion starting in April 2025[92]. - Total net product revenue for Q1 2025 was $13.1 million, a slight increase of 1% from $13.0 million in Q1 2024, driven by $2.0 million from EmrosiTM[99]. - EmrosiTM generated $2.1 million in revenue during its first quarter of commercial launch, offsetting declines in other products like Accutane, which saw a 37% decrease in revenue[99]. - Gross-to-net sales accruals increased to $15.5 million as of March 31, 2025, up from $9.9 million a year earlier, attributed to coupon rebate allowances for EmrosiTM[100]. Financial Performance - Loss from operations improved by 67%, decreasing from $10.1 million in Q1 2024 to $3.3 million in Q1 2025[98]. - The company reported a net loss of $4.1 million for Q1 2025, a 61% reduction compared to a net loss of $10.4 million in Q1 2024[98]. - Operating expenses decreased by 29% from $23.1 million in Q1 2024 to $16.5 million in Q1 2025, primarily due to a 100% reduction in research and development expenses[98]. - Selling, general, and administrative expenses rose by 26% from $8.4 million in Q1 2024 to $10.6 million in Q1 2025[98]. - Interest expense increased by 63% from $548,000 in Q1 2024 to $891,000 in Q1 2025[98]. - Cost of goods sold decreased by $1.2 million, or 20%, to $4.8 million for the three-month period ended March 31, 2025, from $6.0 million for the same period in 2024[101]. Research and Development - Research and development costs were nil in Q1 2025, compared to $7.9 million in Q1 2024, which included Emrosi pre-approval project expenses[103]. - Amortization of acquired intangible assets increased by $0.3 million, or 31%, to $1.1 million for the three-month period ended March 31, 2025, driven by the addition of the Emrosi acquired intangible asset[102]. Cash Flow and Financing - Cash and cash equivalents increased to $21.1 million at March 31, 2025, compared to $20.3 million at December 31, 2024[106]. - Net cash used in operating activities decreased by $2.2 million to $2.8 million for the three-month period ended March 31, 2025, driven by a decrease in net loss[114]. - Net cash flows provided by financing activities increased by $2.0 million to $3.6 million for the three-month period ended March 31, 2025, primarily due to net proceeds from common stock issuances[115]. - Total cash requirements under the SWK Credit Facility include $7.3 million in interest and $25.0 million in principal payments[117]. - The company may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives[108]. Industry and Market Risks - The company operates in a heavily regulated industry, with significant risks related to product development, competition, and market acceptance[89].
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-14 22:10
Group 1 - Journey Medical Corporation reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.24, and an improvement from a loss of $0.53 per share a year ago, representing an earnings surprise of 25% [1] - The company posted revenues of $13.14 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 10.55%, and showing a slight increase from $13.03 million in the same quarter last year [2] - Journey Medical shares have increased approximately 61.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.1% [3] Group 2 - The earnings outlook for Journey Medical is mixed, with the current consensus EPS estimate for the coming quarter at -$0.12 on revenues of $15.1 million, and -$0.41 on revenues of $68.24 million for the current fiscal year [7] - The Medical - Drugs industry, to which Journey Medical belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]
Journey Medical (DERM) - 2025 Q1 - Earnings Call Transcript
2025-05-14 21:32
Financial Data and Key Metrics Changes - Journey Medical reported net product sales of $13.1 million for Q1 2025, a slight increase from $13.0 million in Q1 2024, which included approximately $2.0 million from the initial revenue of AMROCI [6][12] - Gross margin improved to 64% in Q1 2025 from 54% in the prior year, attributed to lower product costs and a favorable sales mix [13] - R&D costs were nil in Q1 2025 compared to $7.9 million in Q1 2024, which included preapproval and milestone payments related to AMROCI [13] - SG&A expenses increased by $2.1 million to $10.6 million in Q1 2025, reflecting investments in commercial infrastructure for the AMROCI launch [13] - Net loss for Q1 2025 was $4.1 million, or $0.18 per share, compared to a net loss of $10.4 million, or $0.53 per share, in Q1 2024 [14][15] - Cash position at the end of Q1 2025 was $21.1 million, up from $20.3 million at the end of 2024 [15] Business Line Data and Key Metrics Changes - The launch of AMROCI is seen as a significant milestone, contributing to initial sales and expected to become the flagship product [6][16] - Legacy products experienced a decline of approximately 10% to 15%, attributed to generic competition [24] - QBREXZA showed strong performance with a 15% increase in prescriptions year-over-year, despite new competition [25][26] - Accutane prescriptions decreased from 93,000 in Q1 2024 to 66,000 in Q1 2025, impacted by new competitors, but showed a 10% growth compared to Q4 2024 [28][30] Market Data and Key Metrics Changes - Approximately 30% of covered commercial insured lives now have access to AMROCI, up from 20% previously [11] - The company actively calls on 83% of dermatology offices that prescribe oral rosacea treatments, leveraging existing brand equity [9] Company Strategy and Development Direction - The company aims to expand access and grow prescription volume for AMROCI while publishing additional peer-reviewed data to support its clinical value [17] - Focus on building brand awareness and ensuring payer coverage to translate prescription momentum into sales [10][11] - The management believes 2025 will be a transformational year for Journey Medical, with a commitment to long-term value creation for patients and shareholders [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the positive initial response to AMROCI and its potential to achieve sustainable EBITDA positivity later in the year [6] - The dermatology-focused sales force is fully trained and actively promoting AMROCI, with early indicators showing over 660 unique healthcare providers writing prescriptions [16][17] - The company is optimistic about the trajectory of AMROCI's launch and expects continued growth in the coming months [40][41] Other Important Information - The Phase III clinical trial results for AMROCI were published in JAMA Dermatology, highlighting its statistical superiority over competitors [8] - The National Rosacea Society updated its treatment algorithms to include AMROCI, signaling confidence from the dermatology community [9] Q&A Session Summary Question: Expectations for AMROCI revenues in Q2 - Management indicated that the initial $2 million in revenue was largely due to stocking and expects additional revenues in Q2 as the product gains traction [20][21] Question: Performance of legacy business - The legacy business is experiencing a decline due to generic competition, with specific products like QBREXZA performing well despite new entrants [24][25] Question: Inventory levels in distribution - Management estimated that inventory levels are typically between two to four weeks during a new product launch [34][36] Question: Early feedback from prescribers - Positive feedback has been received regarding AMROCI's efficacy and tolerability, with many prescribers expressing satisfaction with the product's performance [37][39] Question: Erythema reduction feedback - Anecdotal feedback from dermatologists indicates satisfaction with AMROCI's impact on erythema, although this is not the primary focus of the marketing message [50][51] Question: Repeat prescribers for AMROCI - There is a mix of prescribers, with some writing multiple prescriptions, indicating a positive reception in the market [57]